Harbour Biomed said China’s National Medical Products Administration (NMPA) cleared its IND submission for HBM-7004, enabling the program to enter the clinic for advanced solid tumors. The regulatory green light marks a key step from preclinical development into human testing, with NMPA clearance serving as an early gate for clinical and translational execution in China. HBM-7004’s advancement is notable for oncology investors because early IND activity can drive follow-on funding, partner interest, and trial site ramp-up. The company did not provide additional trial design details in the excerpt, but the clearance itself is the immediate milestone. For stakeholders tracking China’s pipeline cadence, IND approvals remain a primary indicator of which programs are progressing toward proof-of-concept studies and later-stage pivotal development.